血清HBV RNA的临床应用研究进展

摘要/Abstract

摘要： 乙型肝炎病毒(HBV)感染人体后可导致慢性化,这与共价闭合环状DNA(cccDNA)存在密切关系,目前的一线抗HBV治疗药物均不能清除肝内cccDNA,而血清中的HBV RNA能反映cccDNA的转录活性,其作为新的血清学指标在临床上能较好地评估抗病毒疗效,指导停药后复发的治疗方案制订,本文就血清HBV RNA在临床应用方面做一综述。

关键词: HBV RNA, cccDNA, 前基因RNA, 乙型病毒肝炎

周培, 张艳芳. 血清HBV RNA的临床应用研究进展[J]. 肝脏, 2024, 29(5): 602-605.

/ 推荐

[1] European Association for the Study of the Liver.EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection[J].J Hepatol,2017,67(2):370-398.
[2] Liu S,Zhou B,Valdes J D,et al.Serum hepatitis B virus RNA:a new potential biomarker for chronic hepatitis B virus infection[J].Hepatology,2019,69(4):1816-1827.
[3] Guo J T,Guo H.Metabolism and function of hepatitis B virus cccDNA:implications for the development of cccDNA-targeting antiviral therapeutics[J].Antiviral Res,2015,122(10):91-100.
[4] Xia Y,Guo H.Hepatitis B virus cccDNA: formation,regulation and therapeutic potential[J].Antiviral Res,2020,180(8):104824.
[5] Liu Y Y,Liang X S.Progression and status of antiviral monitoring in patients with chronic hepatitis B: from HBsAg to HBV RNA[J]. World J Hepatol,2018,10(9):603-611.
[6] Hong X,Kim E S,Guo H.Epigenetic regulation of hepatitis B virus covalently closed circular DNA: implications for epigenetic therapy against chronic hepatitis B[J].Hepatology,2017,66(6):2066-2077.
[7] Wang J,Shen T,Huang X,et al.Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound[J].J Hepatol,2016,65(4):700-710.
[8] Shen S,Xie Z,Cai D,et al.Biogenesis and molecular characteristics of serum hepatitis B virus RNA[J].PLoS Pathog,2020,16(10):e1008945.
[9] Giersch K,Allweiss L,Volz T,et al.Serum HBV pgRNA as a clinical marker for cccDNA activity[J].J Hepatol,2017,66(2):460-462.
[10] Limothai U,Chuaypen N,Poovorawan K,et al.Reverse transcriptase Droplet digital PCR vs reverse transcriptase quantitative realtime PCR for serum HBV RNA quantification[J].J Med Virol,2020,26(3):3366-3372.
[11] Wang J,Yu Y,Li G,et al.Natural history of serum HBV-RNA in chronic HBV infection[J].J Viral Hepat,2018,25(9):1038-1047.
[12] Wang J,Du M,Huang H,et al.Reply to:“Serum HBV pgRNA as a clinical marker for cccDNA activity”:consistent loss of serum HBV RNA might predict the “Para-functional cure”of chronic hepatitis B[J].J Hepatol,2017;66(2):462-463.
[13] Huang H, Wang J, Li W, et al.Serum HBV DNA plus RNA shows superiority in reflecting the activity of intrahepatic cccDNA in treatment-naïve HBV-infected individuals[J].J Clin Virol,2018,100(3):71-78.
[14] Cloherty G,Butler E,Kuhns M.SerumHepatitis B virus RNA as a potential diagnostic biomarker during chronic hepatitis B virus infection[J].Clin Liver Dis(Hoboken),2019,13(3):90-92.
[15] Wang Y,liu Y,Liao H,et al.Serum HBV DNA plus RNA reflecting cccDNA level before and during NAs treatment in HBeAg positive CHB patients[J]. Int J Med Sci,2022,19(5):858-866.
[16] Huang H X,Wang J,Li W J,et al.Serum HBV DNA plus RNA shows superiority in reflecting the activity of intrahepatic cccDNA in treatment-naïve HBV-infected individuals[J].J Clin Virol,2018,99-100(2-3):71-78.
[17] Wang J,Yu Y Q,Li G J,et al.Relationship between serum HBV-RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients[J].J Hepatol,2018,68(1):16-24.
[18] Farag M S,van Campenhout M J,Pfefferkorn M,et al.Hepatitis B virus RNA as early predictor for response to pegylated interferon alpha in HBeAg-negative chronic hepatitis B[J]. Clin Infect Dis,2021,72(2):202-211.
[19] Jia W,Zhu M Q,Qi X,et al.Serum hepatitis B virus RNA levels as apredictor of HBeAg seroconversion during treatment with peginterferonalfa-2a[J].Virol J,2019,16(1):61.
[20] Jansen L,Kootstra N A,van Dort K A,et al.Hepatitis B virus pregenomic RNA is present in virions in plasma and is associated with a response to pegylated interferon alfa-2a and Nucleos(t)ide analogues[J].J Infect Dis,2016,213(2):224-232.
[21] Van Bommel F,Van Bommel A,Krauel A,et al.Serum HBV RNA as a predictor of peginterferon alfa-2a response in patients with HBeAg-positive chronic hepatitis B[J].J Infect Dis,2018,218(7):1066-1074.
[22] Gao Y,Li Y,Meng Q,et al.Serum hepatitis B virus DNA,RNA,and HBsAg: which correlated better with intrahepatic covalently closed circular DNA before and after Nucleos(t)ide analogue treatment?[J]. J Clin Microbiol,2017,55(10):2972-2982.
[23] Wang Y,Liao H,Deng Z,et al.Serum HBV RNA predicts HBeAg clearance and seroconversion in patients with chronic hepatitis B treated with nucleos(t)ide analogues[J].J Viral Hepat,2022,29(6):420-431.
[24] Luo H,Tan N,Kang Q,et al.Hepatitis B virus pregenomic RNA status can reveal the long-term prognoses of chronic Hepatitis B patients treated with nucleos(t)ideanalogues[J].J Viral Hepat,2020,27(3):323-328.
[25] Chan H L Y, Chan F W S, Hui A J,et al.Switching to peginterferon for chronic hepatitis B patients with hepatitis B e Antigen seroconversionon entecavir-A prospectives study[J].J Viral Hepat,2019,26(1):126-135.
[26] Brakenhoff S M,Robert A,Boonstra A,et al.Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss[J].Aliment Pharmacol Ther,2021,53(2):314-320.
[27] Lim S G,Phyo W W,Cloherty G,et al.Comparative biomarkers for HBsAg loss with antiviral therapy shows dominant influence of quantitative HBsAg (qHBsAg)[J].Aliment Pharmacol Ther,2021,53(1):172-182.
[28] Hou J L,Zhao W,Lee C,et al.Outcomes of long-term treatment of chronic HBV infection with entecavir or other agents from a randomized trial in 24 countries[J].Clin Gastroenterol Hepatol,2020,18(2):457-467.
[29] Brakenhoff S M, De Knegt R J,Van Campenhout M J H,et al.End-of-treatment HBsAg, HBcrAg and HBV RNA predict the risk of off-treatment ALT flares in chronic hepatitis B patients[J].J Microbiol Immunol Infect,2023,56(1):31-39.
[30] Xie Y,Li M H,Feng B,et al.HBeAg-positive patients with HBsAg＜100 IU/mL and negative HBV RNA have lower risk of virological relapse after nucleos(t)ide analogues cessation[J].J Gastroenterol,2021,56(9):856-867.
[31] Zhang Q,Li G J,Zhang J M,et al.Histological response to combination therapy with nucleos(t)ide analogs and peginterferon alpha in treatment-naïve chronic hepatitis B patients[J].J Viral Hepat.2019,26(Suppl1):59-68.
[32] Pan J Q,Tong S M,Kang L,et al.New antihepatitis B virus drugs under development and evaluation[J].Curr Opin in Infect Dis,2016,29(6):632-638.

血清HBV RNA的临床应用研究进展

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 9

编辑推荐

Metrics

本文评价

[1]	刘明, 郭艳, 陈文婷, 况雪梅, 李世炼, 揭丽, 夏杰, 毛青, 朱研. HBeAg阳性妊娠慢性HBV携带者母婴阻断停药后肝炎活动的危险因素研究[J]. 肝脏, 2024, 29(7): 834-839.
[2]	林欣其, 肖丽. HBV pgRNA在慢性乙型肝炎感染者治疗中的临床价值[J]. 肝脏, 2024, 29(2): 240-243.
[3]	梁红妍, 申笙, 孙剑. 靶向HBV cccDNA形成的部分药物研究进展[J]. 肝脏, 2024, 29(1): 3-5.
[4]	梁红妍, 申笙, 孙剑. 靶向cccDNA以实现慢性乙型肝炎治愈[J]. 肝脏, 2023, 28(8): 887-888.
[5]	巩子菱, 邹志强. 血清HBV RNA水平预测抗HBV治疗效果的研究进展[J]. 肝脏, 2023, 28(2): 261-263.
[6]	方芷欣, 邓芮, 孙剑. 血清HBV RNA的基础与临床应用研究进展[J]. 肝脏, 2023, 28(1): 30-32.
[7]	张琪, 王余彦, 秦波. 血清HBV RNA预测慢性乙型肝炎患者停药后复发的meta分析[J]. 肝脏, 2022, 27(6): 647-651.
[8]	马海霞, 赵丽萍, 陈文洁, 胡伟宏, 张世坤. 不同临床结果的乙型肝炎病毒感染者血清前基因组RNA检测的诊断价值[J]. 肝脏, 2021, 26(10): 1150-1153.
[9]	王雪刚, 张新枝, 杨澍, 甘苏琴, 刘诗, 郝坤艳, 周彬, 于乐成. 两种检测HBV RNA方法在核苷(酸)类似物经治和初治慢性乙型肝炎患者中的相关性和一致性评价[J]. 肝脏, 2020, 25(7): 736-742.